Lysosomes are considered as the major degradative site and were recently recognized as dynamic regulators of cellular homeostasis. Many diseases, including cancer, have been linked to functional changes in lysosomes. Natural products and their structural analogs have historically made major contributions to pharmacotherapy. By employing the natural small molecule isowalsuranolide as a chemical probe, the underlying mechanisms of its lysosome-inducing effects were investigated. This study revealed that isowalsuranolide targets TrxR1/2 and triggers lysosomal biogenesis and autophagy via the p53-TFEB/TFE3 axis. This study provides important insight into the lysosomal adaptation mechanism to redox signals and the application of lysosome-inducing agents in the treatment of lysosome-related diseases, including cancer.

Over 7% of Medicare patients travel across state borders for cancer care, though the percentage nearly doubles for rural patients. Tracy Onega says this has major impacts on telehealth policy.

Scientists at St. Jude Children’s Research Hospital used a series of cryo-EM structures to visualize dynamics pivotal to chromatin remodeling, a process implicated in cancer and developmental disorders.

Collaborative research led by investigators at Dana-Farber/Boston Children's Cancer and Blood Disorders Center defines a novel approach to understanding how certain proteins called transcription factors determine which genetic programs will drive cell growth and maturation. The method, called “Perturb-multiome,” uses CRISPR to knock out the function of individual transcription factors across many blood cells at once. The researchers then perform single-cell analyses on each cell to measure the effects of the editing, including identifying which genes have been turned on or off and which genes are accessible (based on epigenetic markers). 

Johns Hopkins Medicine scientists say they have found a pattern of so-called epigenetic “marks” in a transition state between normal and pancreatic cancer cells in mice, and that the normal cells may keep at least a temporary “memory” of those cancer-linked marks. 

BUFFALO, NY – April 4, 2025 – A new research paper was published in Oncotarget, Volume 16, on March 27, 2025, titled “Imipridones ONC201/ONC206 + RT/TMZ triple (IRT) therapy reduces intracranial tumor burden, prolongs survival in orthotopic IDH-WT GBM mouse model, and suppresses MGMT.”